What is Pinealon?
Pinealon is a short tripeptide usually described as Ala-Glu-Asp and grouped with peptide bioregulators. It is discussed for neuroprotection, cognition, and age-related biology. [1][2][3]
Its appeal comes from the small size and bioregulator tradition, not from a robust modern clinical-development program. [1][2][3]
Pinealon needs separation from Epithalon/Epitalon and other Khavinson-style peptides because sequence, target tissue story, and evidence base differ. [1][2][3]
What Pinealon is investigated for
Pinealon evidence is grouped by practical use case and oral route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Cognitive clarity and brain aging support
Oral
Cognitive clarity and brain aging support
Oral
Melatonin and pineal regulation
Oral
Melatonin and pineal regulation
Oral
Evidence snapshot
Overall confidence
Pinealon remains a low-confidence bioregulator entry. The evidence base is mainly older, indirect, or preclinical rather than modern human outcome evidence. [1][2][3][4]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Direct modern human outcome evidence for Pinealon is not established. Human-facing use therefore rests on indirect bioregulator literature. [1][2][3][4]
Animal / preclinical
Animal and mechanistic bioregulator literature supports neuroprotection plausibility, but translation remains uncertain. [1][2][3][4]
Mechanism support
Pinealon is discussed as a short peptide that may influence gene expression and neuronal stress responses. That mechanism is plausible but not enough to establish cognitive or longevity outcomes. [1][2][3][4]
Forms & administration
Pinealon is tracked as an oral short-peptide product. Oral peptide identity, formulation, and market category vary, so protocol context stays product-specific. [5][1][2]
Dosing & protocols
The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.
What to expect
First week
Oral Pinealon use may feel like changes in sleep-wake rhythm, morning energy, concentration, or mental fatigue. [1][2][3][4][5]
Weeks 4-8
Oral cognition-oriented effects may appear as steadier memory routines, daily energy, mood, or sleep regularity. [1][2][3][4][5]
After stopping
Perceived cognition, energy, or sleep-rhythm changes may drift back toward baseline after oral Pinealon use ends. [1][2][3][4][5]
Safety profile
Pinealon safety is an oral neuroactive-peptide question, with sleep, mood, product quality, pregnancy, and repeated cycles driving caution. [1][2][3][4]
Who Pinealon is not for
Route-specific avoid and medical-review notes:
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- Sleep aids / sedatives
Melatonin, antihistamine sleep aids, benzodiazepines, or alcohol can compound grogginess or dream changes; this is a theoretical neuroactive caution. [1][2][3][4]
- Stimulants / nootropics
Stimulants, high-caffeine products, or nootropic stacks can counter sleep effects and confound cognitive tracking; this is a theoretical neuroactive caution. [1][2][3][4]
- Psychiatric medications
Antidepressants, antipsychotics, or mood stabilizers can make mood, sleep, or cognition changes harder to attribute; this is a theoretical neuroactive caution. [1][2][3][4]
Regulatory status
United States
In the U.S. as of 2026-06-21, Pinealon has no FDA-approved drug product for the reviewed oral route. Research-market supply and compounded preparations are separate from approval; the 503A row names the current compounding bucket. [5][6][9][10]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Oral | Not Approved Pinealon is not FDA-approved as an oral drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [5][6][9][10] | Not Listed Pinealon is not in the current reviewed 503A compounding bucket for the oral route; compounding status is separate from FDA drug approval. [5][6][9][10] |
Oral
International
EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [12][13][14][15]
Sports & competition
WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat Pinealon oral route as athlete-cleared without sport-specific review. [7][5][6][9][10]
How it works
Pinealon is a short Ala-Glu-Asp peptide discussed around gene expression, nuclear access, DNA interaction, and neuronal or pineal-cell stress responses. The practical question is whether a very small peptide can shift cell activity enough to matter for aging or cognition. [1][2][3][4]
Oral delivery is the weak link for interpretation. A peptide has to survive product handling and digestion, reach relevant tissue, and produce meaningful exposure before cell-culture or animal mechanisms can support a human longevity or cognitive-performance claim. The mechanism remains background biology, not a protocol-level claim. [1][2][3][4]
Research gaps & open questions
What the current literature has not yet settled about Pinealon:
Common questions
Is Pinealon FDA-approved?
Is Pinealon the same as Epithalon?
Myths & misconceptions
Myth
A three-amino-acid peptide is automatically safe.
Myth
Bioregulator status proves anti-aging benefit.
History & discovery
Pinealon sits in the short-peptide bioregulator tradition, where small tissue-associated peptides were studied for aging, gene-expression, and neuroendocrine effects. Its public story comes from that gerontology literature. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3][4]
Reviews and animal work placed Pinealon near peptide-aging and illumination-regimen studies. That origin explains longevity-market interest, but it does not establish oral human cognitive benefit. [1][2][3][4]
Fluorescent-peptide and pineal-cell culture studies shifted attention toward nuclear entry, DNA interaction, and signaling molecules. Those findings shaped mechanism claims while leaving route and outcome questions open. [1][2][3][4]
7 studies
Peptides and Ageing.
Neuro Endocrinol Lett, 2002. review.
Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens.
Bull Exp Biol Med, 2008 Apr. animal.
Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.
Biochemistry (Mosc), 2011 Nov. in vitro.
Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture.
Bull Exp Biol Med, 2011 Nov. in vitro.
Drugs@FDA/openFDA query for Pinealon
U.S. Food and Drug Administration. database query.
Compounding and the FDA: Questions and Answers
U.S. Food and Drug Administration. official guidance.
The 2026 List of Prohibited Substances and Methods
World Anti-Doping Agency. regulatory.